Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is already on the hunt for bolt-on deals.
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
Post navigation
Previous Post
Onshoring Is Here. The Hiring Wave Is Still a Decade Out